Breast oncology programs sit at the intersection of genomics, surgical oncology, medical oncology, and radiology — and their administrative workflows are correspondingly complex. Coordinating BRCA and multi-gene panel testing for newly diagnosed patients and their at-risk relatives, tracking Oncotype DX and genomic assay results, managing high-risk surveillance schedules for BRCA carriers, and screening patients for clinical trial eligibility all require precise, multi-step coordination that clinical staff rarely have bandwidth to absorb. Virtual assistants (VAs) with breast oncology-specific training are taking on this coordination work with measurable results for program efficiency and patient throughput.
BRCA and Hereditary Panel Testing Coordination
The American Cancer Society estimates that 5% to 10% of breast cancers are hereditary, primarily linked to BRCA1/BRCA2 pathogenic variants. NCCN guidelines recommend genetic testing for patients meeting specific clinical criteria — including triple-negative breast cancer diagnosis under age 60, strong family history, Ashkenazi Jewish ancestry, or male breast cancer diagnosis. Coordinating this testing requires identifying eligible patients, placing genetic counseling referrals, ensuring pre-test counseling occurs before specimen collection, tracking lab turnaround, and scheduling post-test result disclosure appointments.
VAs manage the full testing coordination workflow: flagging new diagnoses against NCCN criteria, generating referral documentation, confirming genetic counseling appointments are completed before testing proceeds, and monitoring laboratory portals for result availability. When results return, VAs schedule post-test counseling and flag positive results for cascade testing discussion — initiating the family notification workflow that genetic counselors lead.
High-Risk Surveillance Scheduling
BRCA1/BRCA2 carriers and individuals with elevated lifetime risk require annual MRI, annual mammography, and semi-annual clinical breast exams, often starting at age 25 to 30. Managing surveillance recall for a population of 100 or more high-risk patients means tracking each individual's imaging schedule, sending reminder outreach, verifying insurance authorization for breast MRI (which often requires high-risk documentation), and reconciling missed appointments with reschedule protocols.
According to a 2023 study in the Journal of Clinical Oncology, high-risk surveillance adherence in academic breast programs averages only 68% when managed by clinical staff alone — a gap that VAs can close through systematic recall management and proactive outreach. VAs maintain high-risk registries, generate monthly recall lists, conduct outreach via phone and patient portal, and document surveillance completion for quality metric reporting.
Oncotype DX and Genomic Assay Result Tracking
Genomic assays — including Oncotype DX Breast Recurrence Score, MammaPrint, and Prosigna — are central to adjuvant chemotherapy decision-making for early-stage hormone receptor-positive breast cancer. After a specimen is submitted to Genomic Health or Veracyte, result turnaround typically runs 10 to 14 days. During that window, VAs track assay submission confirmation, monitor for result availability, notify the oncology team when results post, and ensure the result is documented in the chart ahead of the planned treatment decision appointment.
For programs with high breast cancer volume, managing 15 to 30 concurrent pending assays without a tracking system creates result delay and missed appointment risks. VAs implement and maintain spreadsheet or EHR-based tracking logs, with automated or manual daily checks of laboratory portals.
Clinical Trial Eligibility Screening
Breast oncology programs with active clinical trials — including neoadjuvant immunotherapy trials, PARP inhibitor studies, and CDK4/6 adjuvant trials — require systematic eligibility pre-screening to maintain enrollment pipelines. VAs review new patient intake data against active trial inclusion/exclusion criteria, flag eligible patients for research coordinator review, and maintain tracking of screen-failed versus enrolled patients for sponsor reporting.
The National Cancer Institute's 2024 Clinical Trial Accrual Report found that patient identification delays account for 38% of enrollment gaps in community breast programs. VA-driven pre-screening closes that gap without adding to research coordinator or nurse navigator workload.
For breast oncology programs looking to scale these workflows, Stealth Agents provides virtual assistants trained in hereditary cancer coordination, genomic result tracking, and oncology care navigation.
Sources
- American Cancer Society. "Hereditary Breast and Ovarian Cancer." cancer.org. 2024.
- National Comprehensive Cancer Network. "NCCN Clinical Practice Guidelines: Breast Cancer Risk Reduction." 2025.
- Journal of Clinical Oncology. "High-Risk Breast Surveillance Adherence in Academic Programs." 2023.
- National Cancer Institute. "Clinical Trial Accrual Report." 2024.